• expomed eurasia / March 14th 2022 / İstanbul / Turkey......... • Pharma & Lab Expo / May 24th 2022 / Cairo / Egypt......... • PharmaLytica / June 01st 2022 / Mumbai / India......... • Medlab Expo / Nov 07th 2022 / Riyad / Saudi Arabia.........

Zydus Cadila gets USFDA approval for thyroid drug

Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Liothyronine Sodium tablets USP, 5 mcg, 25 mcg, and 50 mcg, Cadila Healthcare said in a regulatory filing.

23 January, 2021 Mumbai; Drug firm Zydus Cadila has received final approval from the US health regulator to market Liothyronine is a man-made form of thyroid hormone which is used to treat an underactive thyroid (hypothyroidism). It replaces or provides more thyroid hormone, which is normally made by the thyroid gland.

Zydus NSE -1.47 % Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Liothyronine Sodium tablets USP, 5 mcg, 25 mcg, and 50 mcg, Cadila Healthcare said in a regulatory filing.

Zydus Cadila is a part of the Cadila Healthcare group. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad, the company added. The group now has 312 approvals and has so far filed over 390 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04.


×

This Website Uses Cookies for Google Analytics, to improve your experience and to show you personalized advertising. By using this website you agree to our COOKIES AND PRIVACY POLICY...Learn More